HC Wainwright Estimates Immix Biopharma FY2027 Earnings

Immix Biopharma, Inc. (NASDAQ:IMMX) – Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Immix Biopharma in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.20) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.69) per share.

Several other research analysts have also weighed in on IMMX. Bank of America initiated coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 target price for the company. Citigroup assumed coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, Needham & Company LLC initiated coverage on shares of Immix Biopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.43.

Immix Biopharma Trading Up 4.2%

Shares of IMMX opened at $10.13 on Tuesday. The company’s 50-day moving average price is $9.40 and its 200 day moving average price is $8.89. Immix Biopharma has a 12-month low of $1.94 and a 12-month high of $12.14. The firm has a market cap of $551.17 million, a P/E ratio of -11.51 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock worth $1,526,000 after buying an additional 31,625 shares in the last quarter. Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after acquiring an additional 10,950 shares in the last quarter. Imprint Wealth LLC purchased a new stake in shares of Immix Biopharma during the third quarter worth $141,000. Citadel Advisors LLC acquired a new stake in shares of Immix Biopharma in the third quarter valued at $188,000. Finally, Susquehanna International Group LLP raised its stake in shares of Immix Biopharma by 78.8% in the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after acquiring an additional 40,032 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.